Qorvo's Spread Is Pricing Regulatory Drag, Not a Broken Deal

Summary: Qorvo trades below the value of Skyworks' signed cash-and-stock consideration even after both shareholder votes cleared. The market is being paid to underwrite antitrust time, not shareholder uncertainty.

Opportunity Ranking

Rank	Idea	Discovery Lane	Why It May Be Best Now	Evidence Freshness	Catalyst Window	Asymmetry	Main Reason to Reject
1	Qorvo / Skyworks merger spread	liquid U.S. semiconductor merger-arb	QRVO at $90.25 versus $96.28 implied consideration creates a $6.03 spread after shareholder approvals, with the risk concentrated in regulatory timing and remedies.	Live finance snapshot at May 9, 2026, 00:25 Singapore time; Skyworks 10-Q filed after the FTC Second Request.	Regulatory review and expected early-calendar-2027 closing path.	Hedged pair offers about $6.03 upside per QRVO share against a defined break-risk framework.	China, FTC, or remedy risk can make the spread cheap for a reason.
2	Clear Channel Outdoor / $2.43 cash acquisition	U.S. mid-cap cash merger	CCO at $2.385 versus $2.43 cash has a near May 12 vote and clean headline math.	Live finance snapshot at May 9, 2026, 00:25 Singapore time; proxy timetable available.	May 12, 2026 special meeting, then regulatory close path.	Only about 1.9% gross spread before costs.	Too little spread for the regulatory and financing tail relative to QRVO.
3	Kenvue / Kimberly-Clark cash-stock spread	global consumer-health large-cap	KVUE at $17.631 versus about $17.94 implied consideration is liquid and global.	Live finance snapshot at May 9, 2026, 00:25 Singapore time.	Regulatory approvals and expected 2026 closing path.	About 1.7% gross spread, lower event premium.	Lower spread and less urgent surprise; litigation and consumer-health integration risks are not mispriced enough.

Selected opportunity: Qorvo / Skyworks merger spread.

Why this one now: The screen found tighter cash spreads and cleaner votes, but QRVO has the better combination of liquidity, current evidence, spread size, and catalyst structure. At current prices, the signed consideration is about 6.7% above QRVO, while the hedged spread can be framed as a $26.47 net claim on a $32.50 cash leg if the deal closes.

What should surprise the reader: The stock is not mostly pricing a shareholder-vote problem anymore. It is pricing regulatory time, remedy risk, and break-price fear. That is a different trade.

The Setup

Skyworks agreed to acquire Qorvo for $32.50 in cash plus 0.960 Skyworks shares for each Qorvo share. The companies described the combination as a $22 billion U.S.-based analog and RF semiconductor platform when the transaction was announced. The consideration is not a simple cash bid. The stock leg matters, so the cleanest expression is not a naked QRVO long. It is a merger-arb pair: long one QRVO share and short 0.960 SWKS shares.

That structure turns the spread into a more precise question: what is a regulatory-timing claim on $32.50 worth after both sides have already taken the deal to shareholders?

The Market Price

At May 9, 2026, 00:25 Singapore time, the live finance snapshot showed QRVO at $90.25 and SWKS at $66.44. The implied deal value was:

$32.50 + 0.960 * $66.44 = $96.28

That leaves a $6.03 gross spread per QRVO share, or 6.7% of the QRVO long price. On a hedged pair, the current net spread capital is:

$90.25 - 0.960 * $66.44 = $26.47

If the deal closes on current terms and the SWKS short is covered by the received shares, the pair receives $32.50 in cash. The mechanical spread is therefore about $6.03 on $26.47 of net spread capital before borrow, financing, dividends, taxes, slippage, and margin treatment. That is the opportunity, but it is also the trap: this is not a riskless yield. The spread is payment for antitrust uncertainty and break-price path risk.

The Positioning

Positioning evidence is partial, so it should not be overstated. The hard evidence is structural: Starboard Value agreed to support the transaction in the original deal announcement, and the transaction has already moved beyond the most obvious shareholder-vote bottleneck. Current public data do not give a clean, real-time view of merger-arb ownership, borrow cost, dealer gamma, or holder-level hedges.

The spread itself is the live positioning signal. A plain QRVO holder is exposed to SWKS stock movement, deal timing, and break risk. A hedged arb buyer is isolating the cash leg and betting that the FTC and foreign-review path leads to delay, not death. The market is offering that buyer $6.03 per QRVO share because the regulatory clock is not clean.

The Catalyst

The closing mechanism is observable. Skyworks disclosed in its April 2026 Form 10-Q that the parties received an FTC Second Request under the Hart-Scott-Rodino process and expected the transaction to close in early calendar 2027, subject to regulatory approvals and other conditions. The FTC process does not make a deal impossible. It turns timing, remedies, and agency appetite into the main variables.

The next catalysts are not promotional. They are procedural:

Substantial compliance with the FTC Second Request.
Any public indication of remedy discussions or divestiture demands.
Foreign antitrust approvals.
Updated closing guidance from either company.
Any deterioration in Qorvo or Skyworks fundamentals that changes the break-price math.

The key distinction is between delay and prohibition. A delayed close is annoying but potentially profitable. A blocked deal or remedy that destroys the strategic logic is the real loss case.

The Gap

The market appears to price QRVO as if regulatory drag deserves a wide spread after shareholder approvals. The counter-view is that the spread has become too blunt. Semiconductor deals are politically sensitive, and this transaction touches RF, mobile, defense, automotive, and connectivity end markets. That deserves a spread. But a $6.03 spread also assumes that time and remedy risk should dominate the signed economics.

The more precise disagreement is this: if the deal is delayed but not broken, the spread can narrow without needing a new bid, a higher price, or a better semiconductor cycle. It only needs regulatory risk to become less open-ended.

The Payoff Map

One possible expression is long QRVO and short 0.960 SWKS per QRVO share. That expression better matches the thesis than a naked QRVO long because it neutralizes most of the variable stock consideration. It is still exposed to borrow, financing, dividends, margin, corporate-action mechanics, and break spread behavior.

Unhedged QRVO common is a weaker expression because SWKS share-price movement can dominate the deal math. QRVO calls are also less clean: the deal timeline runs into early 2027, so option maturity, implied volatility, and theta can overwhelm the spread.

The bottom case is not "deal does not close, nothing happens." The bottom case is a spread unwind: QRVO sells off as the target, SWKS rallies or at least does not fall enough to offset the short, and the hedge that looked clean during the deal becomes painful during the break.

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Time Horizon	Conditions Required	Evidence Quality
Top Case	30%	Pair net value reaches $32.50 cash value; QRVO implied consideration $96.28 at current SWKS.	+$6.03 per QRVO share; +22.8% on $26.47 net spread capital before costs.	By early calendar 2027.	FTC and foreign reviews clear without value-destructive remedies; companies keep closing guidance intact.	Medium
Base Case	50%	Pair net value marks to $30.50 as spread tightens but close is still pending.	+$4.03 per QRVO share; +15.2% on net spread capital before costs.	3 to 8 months.	Regulatory process remains slow but constructive; no agency complaint; operating results do not damage break-price confidence.	Medium
Bottom Case	20%	Pair net value falls to $14.00 on deal break or remedy shock.	-$12.47 per QRVO share; -47.1% on net spread capital before costs.	Any adverse regulatory event before close.	FTC challenge, foreign block, unacceptable remedy, or material business deterioration.	Medium
Invalidation / Stop Condition	n/a	Spread thesis breaks if QRVO trades below $82 while SWKS trades above $72 without offsetting deal-positive news, or if regulators demand remedies that impair the strategic economics.	Re-underwrite rather than average down.	Immediate on new information.	Public FTC complaint, adverse remedy report, closing guidance withdrawal, or material deterioration in Qorvo fundamentals.	Medium

Probability-weighted expected value: Pair EV is $27.80 versus $26.47 current net entry, or +$1.33 per QRVO share. That is about +5.0% on net spread capital, before borrow, dividends, taxes, margin costs, slippage, and execution frictions. On the QRVO long price, the same expected value is about +1.5%.

Current market price / level: QRVO $90.25; SWKS $66.44; implied consideration $96.28; gross spread $6.03 per QRVO share.

Timestamp: May 9, 2026, 00:25 Singapore time.

Primary instrument: Long QRVO common, short 0.960 SWKS common per QRVO share.

Alternative expressions considered: Unhedged QRVO common, QRVO calls, SWKS common, and tighter lower-return cash spreads in CCO and KVUE.

Confidence: Medium.

What Could Go Wrong

The strongest counterargument is simple: the spread is wide because regulators may have a real problem with this transaction. The combined company would be a large RF and analog semiconductor supplier with exposure to strategic end markets. If the FTC or a foreign regulator sees the asset overlap as structural rather than remediable, the market is not mispricing time. It is pricing a hard stop.

The second risk is break-price math. Qorvo's fiscal fourth-quarter update helps because the company is still operating, repurchasing stock, and generating free cash flow, but that does not make the standalone equity immune. A broken deal can punish the target before investors calmly revalue fundamentals. The pair trade also loses if SWKS rises on relief while QRVO falls on rejection.

Execution matters. The pair needs borrow availability and disciplined sizing. Dividends, corporate-action treatment, tax handling, and margin requirements can change realized returns. The trade is liquid, but the risk is not linear.

What Would Prove This Wrong

This fails if regulators move from information-gathering to active opposition, if remedy demands consume the strategic value of the deal, or if either company withdraws or softens closing guidance. It also fails if Qorvo's standalone fundamentals deteriorate enough that the break price is lower than this map assumes.

The monitoring list is short: FTC posture, foreign-review approvals, company language on timing, and the QRVO/SWKS spread. If the spread widens while both companies still sound constructive, the market may be demanding more risk premium. If it widens on an agency complaint, the thesis has changed.

Bottom Line

The trade is not "long Qorvo because the deal price is higher." The cleaner version is long QRVO and short 0.960 SWKS, a hedged spread that asks whether regulators delay the Skyworks deal or kill it. At current prices, the market is paying about $6.03 per QRVO share to underwrite that distinction. That is enough to be interesting, but only if the position is built as merger-arb risk with a real break case, not as a casual long.

Sources

Source	Use
Live finance quote snapshot, May 9, 2026, 00:25 Singapore time	QRVO, SWKS, CCO, KVUE, KMB market levels used for screening and spread math.
Qorvo investor release, "Skyworks and Qorvo to Combine..."	Signed consideration: $32.50 cash plus 0.960 Skyworks shares per Qorvo share; Starboard support reference; transaction rationale.
Skyworks Form 10-Q for quarter ended April 3, 2026	FTC Second Request disclosure and expected early-calendar-2027 closing path.
Qorvo fiscal 2026 fourth-quarter results release	Current standalone operating evidence and free-cash-flow context for break-price underwriting.
FTC HSR guidance	Mechanics of the Second Request process and why substantial compliance matters.